Ocugen has a vaccine that is already approved in some other countries and is pending approval in the United States and Canada. It looks promising against new variants.
The clinical-stage biotech firm has been co-developing a SARS-CoV-2 vaccine with India's Bharat Biotech, and the latest round of data shows their BBV152 booster neutralizes both the Omicron and Delta variants of the virus that causes COVID-19.
The treatment generated a robust neutralizing antibody response against both strains using a live virus neutralization assay. Test serum results showed the Delta variant was neutralized 100% of the time while Omicron neutralized at a rate of 90%.
|